RhinoCyte™ Inc. is an emerging biopharmaceutical company focused on developing innovative treatments using stem cells taken from the nose lining of adults. The company’s goal is to extend and enhance patients’ quality of life through regenerative medicine treatments, which are those that replace or regenerate human cells, tissues or organs to restore or establish normal function.
Founded in 2006 as a Delaware C Corporation, RhinoCyte’s work promises to one day yield cures for many devastating neurodegenerative disorders, ranging from spinal cord injuries, Parkinson’s disease and amyotrophic lateral sclerosis (ALS) to multiple sclerosis and more. Type 1 diabetes is a primary target as well.
RhinoCyte’s technology is straightforward: Cells are cultured from the olfactory regions of the nasal passageways via outpatient surgery to allow the isolation of progenitors (stem cells), which after growth in the laboratory can be transplanted into the injury site. The technology is safe and effective, as the patient is both the donor and the recipient . This eliminates having to wait for a suitable donor to be found and the need for anti-rejection drugs, which can have many side effects.
In addition, olfactory stem cells are readily accessible and can be stored indefinitely for future use. They also are less likely to develop into tumors than other stem cell sources used for neurodegenerative conditions.
And because the RhinoCyte stem cells originate from tissue donated by patients undergoing routine nasal surgeries, they are free from the issues surrounding embryonic stem cell research.
In The News
RhinoCyte COO to present at ARM/CIRM-sponsored venture capital session
RhinoCyte COO Teresa Leezer is one of only a handful of speakers invited to present at the Regen Med VC Meet-up, an intimate and informal event featuring rapid-fire pitches by an elite group of the regenerative medicine industry’s cutting-edge, early-stage companies. The event is jointly sponsored by the Alliance for Regenerative Medicine and the California Institute of Regenerative Medicine (CIRM). LEARN MORE
Parkinson’s disease cure could be on the horizon in Ali’s own hometown
Just blocks from the center that bears the name of Muhammad Ali — legendary heavyweight champion and the world’s most famous Parkinson’s patient — a group of researchers at RhinoCyte Inc. have made a discovery that could lead to a cure for the disease. Their findings are published in the prestigious journal STEM CELLS Translational Medicine. READ FULL STORY »
RhinoCyte co-founder speaks at World Stem Cell Congress
Dr. Fred Roisen shares important findings that highlight the promise of olfactory stem cells in helping those with spinal cord injuries or Parkinson’s disease. READ FULL STORY »
Perspectives offers commentary and insights on stem cell research and news, contributed by the RhinoCyte team and invited guest experts.
“Stem cells treatment for paralyzed pets shows promise for humans, too” — Dr. Fred Roisen, RhinoCyte CSO and Co-founder
Contact UsEmail: email@example.com
Injury + Medium
Injury + Medium + Cells
Injury + Medium
Injury + Medium + Cells
Meet Our Principals
Fred Roisen, Ph.D., CSO and Co-founder, joined the Department of Anatomical Sciences and Neurobiology at the University of Louisville in 1986. Until recently he served as department chair, stepping down June 30, 2012, to devote full-time to RhinoCyte, which he co-founded in 2006. Dr. Roisen received his degree from Princeton University. Before joining UofL, he was professor and acting chair at Rutgers Medical School.
Contact him: firstname.lastname@example.org • 502.410.0399 • c: 502.558.7449
Teresa Leezer, CEO, brings two decades of executive product, portfolio and company management experience with Roche Labs, Merck & Co. and Bristol Myers Squibb. She has managed products with annual sales exceeding $7 billion, including the worldwide blockbusters Zantac and Aleve, and secured development capital exceeding $12 million from venture, federal and angel financing.
Contact her: email@example.com • 502.569.1068 • c: 502.396.1943
Steve Gailar, Co-founder and Adviser, brings to RhinoCyte more than 40 years of venture capital, management and overall biotech start-up management expertise. He has been a founder/CEO of 10 biomedical startups and raised more than $75 million in venture capital financing with the public market capitalization of his investments exceeding $1 billion.
Contact him: firstname.lastname@example.org • 502.410.4496 • c: 502.741.7009